1. Therapeutic drug monitoring
1.1. Intellectual Property in Discovery
1.2. Targeted drug discovery: Receptor based approaches
1.3. Invitro and invivo testing of new compounds
1.4. Lead optimisation
1.5. Natural Products and Herbal Medicines
2. Medicines Regulation
2.1. General Principles of Medicines Regulation
2.2. Medicines Regulation in the UK
2.3. Medicines Regulation in EU
2.4. The European Medicines Agency and Heads of Medicine Agency
2.5. European Directorate for the Quality of Medicines and Healthcare, the European Pharmacopoeia and the British Pharmacopoeia
2.6. Food and Drug Administration
2.7. Health Canada
2.8. Medicines Regulation in Australia/NZ
2.9. Medicines Regulation in Japan
2.10. Medicines Regulation in China
2.11. Medical Devices Regulation
2.12. Clinical Trials Regulation
2.13. Good Clinical Practice
2.14. Good Laboratory Practice
2.15. Good Manufacturing Practice
2.16. Ethics Committee (European Union)
2.17. Institutional Review Board (US)
2.18. Marketing Authorisation Applications and updating and maintaining Licences
2.19. International Conference on Harmonisation
2.20. Common Technical Document
2.21. Medicinal Product Information in the EU
2.22. Summary of Product Characteristics
2.23. Orphan Drugs
2.24. Paediatric Investigational Plan
2.25. Regulatory Requirements for Pharmacovigilance
2.26. Overview of Reporting of Adverse Drug Reactions
2.27. Non-prescription Drugs
2.28. Provision of Unlicensed Medicines
2.29. Reclassification Of Drugs
2.30. Parallel imports
3. Clinical Pharmacology
3.1. ADME
3.2. Volume of distribution, clearance, half-life
3.3. Pre-clinical aspects of pharmacokinetics
3.4. Non-clinical data
3.5. Clinical aspects of pharmacokinetics
3.6. Dose Response Relationship
3.7. Proof of concept studies
3.8. Reproductive Toxicity Studies
3.9. Immunotoxicity studies
3.10. Carcinogenicity
3.11. Genotoxicity testing
3.12. Local Tolerance
3.13. Acute Toxicity
3.14. Studies - objectives, design, conduct and analysis
3.15. Populations for exploratory studies and planning of exploratory studies
3.16. Pharmacodynamic endpoints
3.17. Bioequivalence
3.18. Evaluation of safety and tolerability
3.19. Hypersensitivity reactions
3.20. Drug-drug interactions
3.21. Ethics in Research: Basic principles, Declaration of Helsinki and CIOMS
3.22. Disease Models
3.23. Biomarkers
3.24. Pharmacogenetics
3.25. Population Pharmacokinetics
3.26. Small molecules and biologicals - safety / pharmacology requirements
4. Clinical Development
4.1. Requirements for licensing and new medicinal product
4.2. Regulatory Guidance
4.3. General principles of clinical trial protocols
4.4. Clinical Study Design
4.5. Adaptive trial designs
4.6. Informed consent
4.7. Data Protection
4.8. Indemnity and compensation
4.9. Investigators Brochure
4.10. Organisation of project teams / project planning
4.11. Contractual arrangements with research sites and Contract Research Organisations
4.12. Case Report Form (CRF)
4.13. Budgeting and cost control
4.14. Expanded access programs
4.15. Study master file preparation
4.16. Target product profile
5. Statistics and Data management
5.1. Determining the sample size in a clinical trial
5.2. Sensitivity and Specificity
5.3. Significance testing
5.4. Type I and Type II error
5.5. Confidence intervals
5.6. Minimising Bias
5.7. Paired and Unpaired t-test
5.8. Parametric and non parametric tests
5.9. Patient Reported Outcomes
5.10. Health Related Quality of life (HRQL)
5.11. Clinical Interpretation of Trial Results
5.12. Clinical Study Report
5.13. Issues with making trial results available
5.14. Interim Analysis
5.15. Data Management
5.16. Within-Trial Data Management
6. Drug Safety and Pharmacovigilance
6.1. Regulatory Requirements for Pharmacovigilance 6.1
6.2. Key pharmacovigilance regulations in the EU
6.3. Volume 9A
6.4. Periodic Safety Update Reports
6.5. Benefit Risk Assessment
6.6. Pharmacoepidemiological Safety Data
6.7. Product Suspension and Withdrawal & Defective Medicines
6.8. Safety Signal
6.9. Spontaneous Reporting
6.10. Post Authorisation Safety Studies (PASS)
6.11. Dear Healthcare Professional Communication
6.12. Issues and crisis management
6.13. Adverse Events in Clinical Trials
6.14. Risk Management
7. Healthcare Marketplace
7.1. Marketing Medicines: The drug Lifecycle
7.2. FCPA and Bribery act
7.3. Product life cycle management
7.4. Ethical marketing of medicines
7.5. World Health Organisation (WHO) Ethical Criteria for Medicinal Drug Promotional
7.6. Co-marketing
7.7. Inlicensing
7.8. The Association of British Pharmaceutical Industries (ABPI)
7.9. The ABPI Code of Practice
7.10. PhRMA
7.11. IFPMA code of practice
7.12. The European Federation of Pharmaceutical Industries and Associations (EFPIA)
7.13. Medicines Australia
7.14. The National Institute for Health and Clinical Excellence (NICE)
7.15. The Scottish Intercollegiate Guidelines Network (SIGN)
7.16. IQWIG
7.17. Health Economics
7.18. Quality adjusted life years
7.19. Pharmacoepidemiology
7.20. Branded generics
7.21. Intellectual property
7.22. Product liability and compensation
8. Therapeutics
8.1. Medicines for Children
8.2. Medicines in pregnancy
8.3. Medicines in the elderly
8.4. Medicines for patients with hepatic impairment
8.5. Medicines for patients with renal impairment
8.6. Principles of Risk Benefit
8.7. Therapeutic drug monitoring